Amneal Pharmaceuticals (AMRX): Time to Buy this HEALTHY Growth Stock

I recently increased my allocation to healthcare stocks. That’s because the easy gains stage of this bull market is now over. 

Now it will likely be a more volatile path forward. Kind of like 2 steps forward and 1 step back. 

One of the best groups to navigate that extra volatility is healthcare. Especially a growth oriented company like Amneal Pharmaceuticals (AMRX) that will have appeal during times of greed as well as fear. 

Let’s focus on that growth story. 

Right now they are expected to grow earnings 38% year over year. For as strong as that sounds, please remember they have averaged a 33% beat the past few quarters. So likely earnings growth will end up even higher than expected. 

One major growth catalyst has been the launch of CREXONT (for Parkinson’s disease), which management highlighted as a standout contributor. Other newer products, including injectable and complex medicines (not just plain tablets), are also gaining traction. 

All in all, the che company leverages its ability to make “complex dosage forms” — injectables, inhalants, ophthalmics, etc. — which limits competition and tends to command better margins. 

The Zen Ratings is certainly appreciating the fundamental prowess of these shares given that it is the #11 rated stock out of nearly 4,600. 

So not just top 5% of all stocks analyzed, which is the minimum threshold for all A rated stocks. But actually in the 99.77 percentile. Rarified air indeed. 

This is a story of having no weakness across the 7 component grades. Nothing is lower than the top third of all stocks. 

Whereas its strength is Growth, Momentum and Sentiment (all top 10% or higher). Value is not far off the mark at top 14%. 

Add it altogether and you can easily appreciate my excitement in AMRX. 

Truly it has the look of a stock with the potential to double in the next couple of years given its special fundamental profile. This is especially true if it keeps up those robust 33% earnings beats. 

What To Do Next?

Amneal Pharmaceuticals (AMRX) is just one of 20 stellar stocks found in my Zen Investor portfolio.

Each stock was selected by harnessing the power of the Zen Ratings along with my 45 years of successful investing experience. 

This dynamic combination has us pinpointing stocks with the unique opportunity to double or more in the next 1-2 years. 

If that appeals to you, then please click below to learn more about my investment process…and how to see my current top 20 stock recommendations. 

Discover the Zen Investor portfolio & Top 20 Stocks Now > 

One more thing for today…

Please be sure to join me this coming Wednesday, December 10th for my timely presentation:

2026 Stock Market Outlook > 

Yes, now is the perfect time to get your house in order for the coming year. 

First, we need to review the bull vs. bear case for 2026. Unfortunately there are signs in the economy that say things could get downright ugly. 

Then we will talk about the perfect trading plan to stay on the right side of the action, along with my top picks for the year ahead. 

Just click below to claim your spot for this vital event on Wednesday…

2026 Stock Market Outlook > 

Wishing you a world of investment success!

Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)

Editor of the Zen Investor

Want to get in touch? Email us at news@wallstreetzen.com.